{
    "clinical_study": {
        "@rank": "45037", 
        "arm_group": [
            {
                "arm_group_label": "AIC316", 
                "arm_group_type": "Experimental", 
                "description": "100 mg once daily for 28 days"
            }, 
            {
                "arm_group_label": "Valacyclovir", 
                "arm_group_type": "Active Comparator", 
                "description": "500 mg once daily for 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the safety and efficacy of AIC316 100 mg once daily\n      compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding."
        }, 
        "brief_title": "Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Genital Herpes", 
        "condition_browse": {
            "mesh_term": "Herpes Genitalis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult, immunocompetent men and women in good health of any ethnic group\n\n          -  Seropositive for Herpes Simplex Virus Type 2 (HSV-2)\n\n          -  History of recurrent episodes (>=4 to <=9) of genital herpes for at least 12 months\n\n        Exclusion Criteria:\n\n          -  Present episode of genital herpes at time of randomization\n\n          -  Clinically relevant acute or chronic infections (excluding HSV-2)\n\n          -  Known intolerance to valacyclovir, acyclovir, or any component of the formulation\n\n          -  Documented HSV resistance to acyclovir, valacyclovir, famciclovir or penciclovir"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "91", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658826", 
            "org_study_id": "AIC316-01-II-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "AIC316", 
                "description": "oral administration", 
                "intervention_name": "AIC316", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Valacyclovir", 
                "description": "oral administration", 
                "intervention_name": "Valacyclovir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valacyclovir", 
                "Acyclovir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AIC316", 
            "Viral shedding"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University School of Medicine, IU Infectious Diseases Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Westover Heights Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas Health Science Centre, Center for Clincial Studies"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "University of Washington, Virology Research Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Within-subject genital HSV mucocutaneous shedding rate: number of HSV positive swabs per subject relative to the total number of swabs collected per subject.", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658826"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AiCuris GmbH & Co.KG", 
        "sponsors": {
            "collaborator": {
                "agency": "Medpace, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AiCuris GmbH & Co.KG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}